NCT07263308 (ARISE-2) is a Phase 3 clinical trial of Albumin in Acute Ischemic Stroke, sponsored by Capital Medical University.

Who is sponsoring NCT07263308?

NCT07263308 is sponsored by Capital Medical University.

What drugs are being tested in NCT07263308?

Interventions in NCT07263308: Albumin, Endovascular treatment.

What condition does NCT07263308 study?

NCT07263308 studies Acute Ischemic Stroke.

Is NCT07263308 still recruiting?

NCT07263308 is currently recruiting now. Last updated 15 April 2026.

Last reviewed 2026-04-15 · How we verify

NCT07263308: ARISE-2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2

Recruiting now Phase 3 Last updated 15 April 2026

What this trial tests

Phase 3 trial testing Albumin in Acute Ischemic Stroke in 1,192 participants. Currently enrolling.

Timeline

18 December 2025

Primary endpoint
20 June 2027

1 December 2027

Quick facts

Lead sponsor	Capital Medical University
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	1,192
Start date	18 December 2025
Primary completion	20 June 2027
Estimated completion	1 December 2027
Sites	12 locations across China

Drugs / interventions tested

Albumin — full drug profile →
Endovascular treatment

Conditions studied

Acute Ischemic Stroke — all drugs for Acute Ischemic Stroke →

Sponsor

Capital Medical University

Who can join

Adults 18 to 80, any sex, with Acute Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, multicenter, open-label, randomized controlled clinical trial. The investigators will apply albumin to the reperfusion treatment of patients with acute ischemic stroke in the anterior circulation. This study aims to verify the efficacy and safety of albumin combined with endovascular treatment in patients with anterior circulation acute ischemic stroke.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Albumin

Trials testing the same drug.

NCT07395141 — Albumin in Acute Variceal Bleeding · Phase 3 · not yet recruiting
NCT07002827 — Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standar · NA · not yet recruiting
NCT06809088 — Comparison of Safety and Efficacy of Tailored Versus Fixed Dose Albumin for the Management of Patients With Cirrhosis an · NA · not yet recruiting
NCT06654687 — Transthoracic Echocardiographic Monitoring of Cardiac Output Effects of Colloid Preload and Crystalloid Coload During Ce · NA · completed
NCT06245590 — Evaluation of Low-dose Albumin and Midodrine Versus Midodrine Alone in Outcome of Recurrent Ascites in Patients With Dec · NA · unknown

Other recruiting trials for Acute Ischemic Stroke

Currently open trials in the same condition.

NCT07115940 — Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours · NA · recruiting
NCT07404852 — Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemi · NA · recruiting
NCT07361302 — A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Pe · Phase 3 · recruiting
NCT07436156 — SUMMIT RISE Study of Acute Ischemic Stroke Patients · Phase 4 · recruiting
NCT07203625 — Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours · Phase 4 · recruiting

Other Capital Medical University trials

Trials by the same sponsor.

NCT07379437 — Haematococcus Pluvialis Astaxanthin for Brain Aging · NA · not yet recruiting
NCT07531394 — Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Myocardial Injury Following Acute Ischemic St · Phase 3 · not yet recruiting
NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07495358 — Development and Usability Evaluation of a Knowledge Graph-Based Symptom Management System for Patients With Breast Cance · NA · not yet recruiting
NCT07513233 — Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL) · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07263308 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Capital Medical University
Last refreshed: 15 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07263308.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing